⮢ Back
PREPARE study: Personalised medication reduces side effects by 30%
The PREPARE study (PREemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions) investigated the use of a drug passport that includes genotyping of 12 genes and 50 genetic variants that affect how drugs are broken down in the body.
The study, which involved 6,944 patients from seven European countries, suggests that the use of a personalised drug passport can reduce the number of adverse drug reactions in the treatment of depression by 30%.
Funding took place under the European Horizon 2020 research and innovation program. The UPGx consortium received a grant of 14.5 million euros for the project. “Horizon 2020” is the largest research and innovation program of the European Union and aims to promote innovation and scientific excellence in Europe.
PGXperts InteractionCheck – individualised medication with pharmacogenetic
With PGXperts InteractionCheck, interaction risks between drugs, active ingredients, foods and lifestyle habits as well as genetic variations can be identified in less than 1 minute. Interactions are clearly classified according to their severity and described in detail. The clear presentation of genetic interaction risks allows rapid identification of patients who could benefit from pharmacogenetic analysis. The InteractionCheck is available as a web application and for Android and iOS devices. It can thus be used both as an inpatient tool and on the road, for example, during home visits or emergency interventions.
For more information about the PGXperts InteractionCheck, please visit: www.pgxperts.com
More information about U-PGx and the results of the PREPARE study can be found at: https://upgx.eu/results/